Ramucirumab‐induced ascites with endothelial growth factor receptor mutation‐positive non‐small cell lung cancer: Two case reports.

Autor:	Shiraha, Keisuke, Tamura, Tomoki, Koyanagi, Taisaku, Umeno, Takahiro, Nishii, Kazuya, Kuyama, Shoichi
Předmět:	EPIDERMAL growth factor receptors ENDOTHELIAL growth factors EPIDERMAL growth factor LUNG cancer MEDICAL personnel
Zdroj:	Respirology Case Reports; Oct2024, Vol. 12 Issue 10, p1-5, 5p
Abstrakt:	Ramucirumab (RAM) has been approved for the treatment of non‐small cell lung cancer (NSCLC). Here, we report two cases of RAM‐induced ascites with epidermal growth factor receptor‐mutant NSCLC. Patient 1, a 72‐year‐old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83‐year‐old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM‐induced ascites in patients with NSCLC and should appropriately manage it. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.